ABCL FY 2020 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$233M+1907.9% YoY

Gross Profit

$206M88.4% margin

Operating Income

$156M66.9% margin

Net Income

$119M51.0% margin

EPS (Diluted)

$0.45

Cash Flow

Operating Cash Flow

$23M

Free Cash Flow

$8M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$175M

Stockholders' Equity

$831M

Cash & Equivalents

$594M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$233M	$12M	+1907.9%
Gross Profit	$206M	$12M	+1674.1%
Operating Income	$156M	-$4M	+3889.9%
Net Income	$119M	-$2M	+5478.5%